LNPs’ wide applications are supported by attributes such as elevated biocompatibility, improved bioavailability, and enhanced therapeutic effectiveness. Thanks to these characteristics, several LNP-encapsulated drug products have received approval from both the FDA and EMA and are currently available on the market, with the recent COVID-19 vaccination to be a prominent example of their potential.
- In vitro case study
The following in vivo study demonstrates that archaeal ether lipids significantly enhance mRNA lipid nanoparticle (LNP) technology by improving particle internalization and protein expression levels. The findings suggest that archaeal ether lipids could serve as promising next-generation LNP components by improving the efficiency and stability of existing formulations.
Figure: Increase particle uptake and increased expression of GDGT and TEL containing LNPs in C2C12 cells.
- In vivo case study
NovoArc conducted an in vivo study in rats, using a commercial LNP formulation mixed with GDGT lipid in addition. The formulation containing GDGT shows a 2-fold increase bioavailability and a prolonged release of mRNA induced EPO, shown in the diagram below. In vitro and in vivo results proof the beneficial properties of tetraether containing LNPs.
To ensure the safety of tetraether lipids, a in vivo Tox study was executed and the results are currently evaluated. For more information and data on the safety and efficiency of our tetraether lipids feel free to get in touch with us. We are more than happy to share more promising results.